Compare NRGV & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NRGV | LBRX |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | 27 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 731.4M | 850.5M |
| IPO Year | 2021 | N/A |
| Metric | NRGV | LBRX |
|---|---|---|
| Price | $5.30 | $28.63 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $2.00 | ★ $46.60 |
| AVG Volume (30 Days) | ★ 4.7M | 127.3K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.57 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $203,671,000.00 | N/A |
| Revenue This Year | $28.93 | N/A |
| Revenue Next Year | $16.69 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 340.86 | N/A |
| 52 Week Low | $0.70 | $13.40 |
| 52 Week High | $6.40 | $33.47 |
| Indicator | NRGV | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 57.64 | 45.74 |
| Support Level | $2.95 | $22.39 |
| Resistance Level | $5.73 | $33.47 |
| Average True Range (ATR) | 0.55 | 1.64 |
| MACD | -0.05 | -0.58 |
| Stochastic Oscillator | 56.98 | 30.06 |
Energy Vault Holdings Inc is a diversified portfolio of energy storage solutions to third parties, including proprietary gravity, battery, and green hydrogen-based technologies, supported by technology-agnostic energy management software and integration capabilities. Geographical presence in the United States, Australia, and other countries. The majority of its revenue comes from Australia.
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.